Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Status:
Completed
Trial end date:
2017-10-26
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow
the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1).
Additionally, the safety of RAD001 will be studied.
The study drug, RAD001, is a drug that may act directly on tumor cells by preventing tumor
cell growth and development. RAD001 has been studied in participants with various types of
cancer as a single agent (a drug that is used alone to treat the cancer) or in combination
with a number of well known anticancer therapies. Information from these research studies
suggests that RAD001 may help to shrink or slow the growth of low-grade gliomas.
In this research study, the investigators are looking to see the response of RAD001 in
children with low-grade gliomas and NF1 that have either not responded to treatment or have
come back after treatment. We are also looking for the highest dose of RAD001 that can be
given safely in this patient population.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
Ann & Robert H Lurie Children's Hospital of Chicago Boston Children's Hospital Boston Children’s Hospital Children's Hospital Los Angeles Children's Hospital Medical Center, Cincinnati Children's Hospital of Philadelphia Children's National Research Institute Children's Research Institute National Cancer Institute (NCI) New York University School of Medicine NYU Langone Health University of Chicago University of Utah Washington University School of Medicine